181 related articles for article (PubMed ID: 11349508)
1. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?].
Hernández G; Altermatt F; Bernucci F; Acuña D; Apablaza F; Valenzuela F; Lefio A; Pérez C; Bugedo G; Castillo L
Rev Med Chil; 2000 Oct; 128(10):1101-7. PubMed ID: 11349508
[TBL] [Abstract][Full Text] [Related]
2. Case-control study of amphotericin B in a triglyceride fat emulsion versus conventional amphotericin B in patients with AIDS.
Manfredi R; Chiodo F
Pharmacotherapy; 1998; 18(5):1087-92. PubMed ID: 9758320
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B infused in 20% lipid emulsion.
Ryan KA
J Intraven Nurs; 1996; 19(3):123-5. PubMed ID: 8788829
[TBL] [Abstract][Full Text] [Related]
4. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.
Pascual B; Ayestaran A; Montoro JB; Oliveras J; Estibalez A; Julia A; Lopez A
Ann Pharmacother; 1995 Dec; 29(12):1197-201. PubMed ID: 8672820
[TBL] [Abstract][Full Text] [Related]
5. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients.
Sorkine P; Nagar H; Weinbroum A; Setton A; Israitel E; Scarlatt A; Silbiger A; Rudick V; Kluger Y; Halpern P
Crit Care Med; 1996 Aug; 24(8):1311-5. PubMed ID: 8706484
[TBL] [Abstract][Full Text] [Related]
6. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar.
Sundar S; Chakravarty J; Agarwal D; Shah A; Agrawal N; Rai M
Trop Med Int Health; 2008 Sep; 13(9):1208-12. PubMed ID: 18664241
[TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity of amphotericin B administered to dogs in a fat emulsion versus five percent dextrose solution.
Randall SR; Adams LG; White MR; DeNicola DB
Am J Vet Res; 1996 Jul; 57(7):1054-8. PubMed ID: 8807021
[TBL] [Abstract][Full Text] [Related]
8. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
9. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
10. [Amphotericin B into parenteral lipid emulsions. Galenic stability of mixtures. Preliminary results].
Blancard A; Monges P; Lacarelle B; Denis JP; Bongrand MC; Ragon CH; Gouin F
Pathol Biol (Paris); 1996 May; 44(5):384-8. PubMed ID: 8758481
[TBL] [Abstract][Full Text] [Related]
11. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
Schöffski P; Freund M; Wunder R; Petersen D; Köhne CH; Hecker H; Schubert U; Ganser A
BMJ; 1998 Aug; 317(7155):379-84. PubMed ID: 9694753
[TBL] [Abstract][Full Text] [Related]
12. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations.
Linder N; Klinger G; Shalit I; Levy I; Ashkenazi S; Haski G; Levit O; Sirota L
J Antimicrob Chemother; 2003 Oct; 52(4):663-7. PubMed ID: 12972450
[TBL] [Abstract][Full Text] [Related]
13. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
[TBL] [Abstract][Full Text] [Related]
14. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
15. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients.
Nucci M; Loureiro M; Silveira F; Casali AR; Bouzas LF; Velasco E; Spector N; Pulcheri W
Antimicrob Agents Chemother; 1999 Jun; 43(6):1445-8. PubMed ID: 10348768
[TBL] [Abstract][Full Text] [Related]
17. In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits.
Chavanet P; Duong M; Buisson M; Hamel H; Dubois C; Bonnin A; Portier H
J Antimicrob Chemother; 1997 Mar; 39(3):427-30. PubMed ID: 9096196
[TBL] [Abstract][Full Text] [Related]
18. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
Chavanet PY; Garry I; Charlier N; Caillot D; Kisterman JP; D'Athis M; Portier H
BMJ; 1992 Oct; 305(6859):921-5. PubMed ID: 1458072
[TBL] [Abstract][Full Text] [Related]
19. [Safety of long-term administration of conventional amphotericin B in oncology patients].
Doubek M; Mayer J; Horký D
Cas Lek Cesk; 2002 Mar; 141(5):156-9. PubMed ID: 11998223
[TBL] [Abstract][Full Text] [Related]
20. A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients.
Barquist E; Fein E; Shadick D; Johnson J; Clark J; Shatz D
J Trauma; 1999 Aug; 47(2):336-40. PubMed ID: 10452470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]